Wiersinga W M, Endert E, Trip M D, Verhaest-de Jong N
Clin Chem. 1986 Mar;32(3):433-6.
We measured thyrotropin in plasma by an ultrasensitive immunoradiometric assay (TSH-IRMA, "Sucrosep," Boots-Celltech), before and after thyroliberin (TRH) stimulation, in 71 patients with suspected thyroid-function disorders. Thirty-three were taking amiodarone; none was receiving (anti)thyroid drugs. The patients were divided into four groups, according to their TSH response to TRH (as measured previously by conventional TSH-RIA) and the concentrations of thyroxin (T4) and triiodothyronine (T3) in their plasma. Observed ranges of plasma TSH-IRMA (milli-int. units/L) before and after TRH were: euthyroid (n = 20), 0.2-3.0 and 1.7-15.5; subclinically hypothyroid (n = 14), 4.3-18.5 and 20-75; hyperthyroid (n = 17), less than 0.09 and less than 0.09-0.4; and subclinically hyperthyroid (n = 20), less than 0.09-1.1 and less than 0.09-2.6. Evidently TSH-IRMA results for a single sample completely distinguish hyperthyroidism from euthyroidism. However, TSH-IRMA values may also be undetectable in subclinical hyperthyroidism. The TSH response to TRH can be predicted from basal TSH-IRMA results less than 0.09 or greater than or equal to 0.8 milli-int. unit/L, intermediate values can be associated with either a normal TSH response (euthyroidism) or a decreased TSH response (subclinical hyperthyroidism only). We advocate TSH-IRMA as the first diagnostic test of thyroid function for amiodarone-treated patients.
我们采用超敏免疫放射分析法(TSH-IRMA,“Sucrosep”,Boots-Celltech),在促甲状腺素释放激素(TRH)刺激前后,对71例疑似甲状腺功能紊乱患者的血浆促甲状腺激素进行了检测。33例患者正在服用胺碘酮;无人正在接受(抗)甲状腺药物治疗。根据患者对TRH的促甲状腺激素反应(此前通过传统促甲状腺激素放射免疫分析法测定)以及其血浆中甲状腺素(T4)和三碘甲状腺原氨酸(T3)的浓度,将患者分为四组。TRH刺激前后血浆TSH-IRMA(毫国际单位/升)的观察范围为:甲状腺功能正常者(n = 20),0.2 - 3.0和1.7 - 15.5;亚临床甲状腺功能减退者(n = 14),4.3 - 18.5和20 - 75;甲状腺功能亢进者(n = 17),小于0.09和小于0.09 - 0.4;亚临床甲状腺功能亢进者(n = 20),小于0.09 - 1.1和小于0.09 - 2.6。显然,单个样本的TSH-IRMA结果可完全区分甲状腺功能亢进与甲状腺功能正常。然而,在亚临床甲状腺功能亢进中,TSH-IRMA值也可能检测不到。根据基础TSH-IRMA结果小于0.09或大于或等于0.8毫国际单位/升,可预测对TRH的促甲状腺激素反应,中间值可能与正常促甲状腺激素反应(甲状腺功能正常)或促甲状腺激素反应降低(仅亚临床甲状腺功能亢进)相关。我们提倡将TSH-IRMA作为胺碘酮治疗患者甲状腺功能的首选诊断检测方法。